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in Italy. In this study, the antibody response of 133 patients
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investigated. Antibody titres were periodically scored up to 1
year since the infection: 82.7% of the IgM antibody disappeared
within 12 months, and the IgG response lasted longer than 12
months. Nevertheless, the IgG mean titre was lower in 95.5% of
patients at the end of follow-up, thus suggesting a decrease
within a relatively short period.
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This is an open access artiIntroductionChikungunya virus (CHIKV), an arthropod-borne virus (Toga-
viridae family) transmitted by Aedes spp. mosquitoes [1], rep-
resents an important reemerging public health problem in both
tropical and temperate countries [2,3]. The ﬁrst epidemic in a
temperate area was reported in the Emilia-Romagna region of
northeastern Italy in summer 2007 [4,5]. An active surveillance
system for the identiﬁcation of all suspected cases (patients
with fever and joint paint) was implemented during the event,
with suspected cases conﬁrmed with molecular and serologic
tests by the Clinical Microbiology Unit, Regional Reference
Centre for Microbiological Emergencies, St Orsola-Malpighi
University Hospital, Bologna.
During the course of CHIKV infection in humans, an anti-
body response develops in the early stages, but its persistence
over time is not fully established [6], as differences in the length
of permanence after onset of symptoms and in relation to the
method used to measure CHIKV antibodies have been re-
ported [6–8].
As far as the epidemiology of CHIKV occurring in areas that
are not tropical is concerned, to our knowledge, ours is the
ﬁrst study to report on the lasting period of speciﬁc immu-
noresponse in a population of patients followed since the
beginning of the acute onset of the disease in a temperate zone
with autochthonous transmission.
We report the results of a serologic follow-up aimed at
estimating the modiﬁcation of the CHIKV-speciﬁc antibody ti-
tres with a follow-up time lasting 12 months since the acute
phase.
This study was submitted to the Area Vasta Romagna ethical
committee for approval (which was provided on 12 December
2007), and all participants signed an informed consent form.MethodsThe study population was composed of 133 patients for whom
the history of CHIKV infection was recorded, as previously
described [9]. Inclusion criteria included clinical evidence of
CHIKV infection [9] and detection of an anti-CHIKV-speciﬁc
IgM titre of 1/100 with a negative IgG response or the
detection of CHIKV RNA in serum in the acute stage. All pa-
tients who met these criteria were enrolled and followed up as
described below.
Of the 133 subjects included, 70 (52.6%) were female. Serum
samples (three for each patient) were collected between
September–December 2007 and September–December 2008,New Microbe and New Infect 2015; 7: 23–25
sevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases
cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
http://dx.doi.org/10.1016/j.nmni.2015.04.002
24 New Microbes and New Infections, Volume 7 Number C, September 2015 NMNIas previously described [9], within subsequent intervals of 2
months, 4–5 months and 12–13 months after the clinical onset
of the infection. The anti-CHIKV-speciﬁc IgM and IgG antibodies
were detected and titrated by a commercially available ELISA
following the manufacturer’s instructions (Diesse, Siena, Italy).Results and discussionAt the ﬁrst follow-up at 2 months, 94 (70.7%) patients were
positive for both IgM and IgG and 39 (29.3%) were positive for
IgM only. In these samples, the IgM-positive specimens had a
titre ranging from 1/100 to 1/12 800 (Fig. 1), and the IgG
positive titres ranged between negative and 1/12 800 (Fig. 2).
In the second sampling of this study (4–5 months from the
acute stage), 93 (70%) patients were positive for both IgM and
IgG, no sample was positive for IgM only and 40 (30%) were
positive only for IgG. The IgM titres varied between negative
and 1/1600 (Fig. 1) and the IgG titres ranged from 1/1600 to 1/
102 400 (Fig. 2).
Finally, in the third sampling (12–13 months after the acute
stage), 23 (17.3%) samples still showed an IgM and IgG immu-
noresponse, no sample was positive for IgM only (as expected,
given the data collected during the second sampling) and 110
(82.7%) were positive for IgG only. The IgM-positive samples
showed titres between negative and 1/200 (Fig. 1), while IgG
titres varied between 1/100 and 1/12 800 (Fig. 2).
The results obtained at the end of the follow-up period
clearly suggested that the IgG antibody titres decreased startingFIG. 1. Variation of the IgM antibody titres in the three follow-up sampling
(CHIKV) infection. For each follow-up group of specimens, the mean value o
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samples. In addition, 110 (82.7%) patients showed a completely
negative IgM response. Only in six (4.5%) patients did the IgG
titre not show a modiﬁcation: ﬁve patients demonstrated a
stable titre, and in only one was the IgG titre increased. Samples
that were still IgM positive at the end of follow-up (17.3%)
showed quite a low titre (1/100–1/200) (Fig. 1). No sample
became negative for IgG within the follow-up time frame,
although the mean titre was considerably lower (about 4 times
lower) than in the second sampling (Fig. 2). We stress that all
specimens obtained during follow-up were tested in triplicate at
the end of this period in two separate runs.
In addition, we believe that 1 year after the acute phase, the
anti-CHIKV IgG response is mainly represented by neutralizing
antibodies. Data in the literature show that neutralizing anti-
bodies circulate up to 12 months after the acute stage [6,7] and
that even in the presence of titres lower than those identiﬁed in
the present study at the third sampling, this immunoresponse is
still capable of neutralizing CHIKV in vitro [10].
In conclusion, this study showed that up to 1 year after the
acute stage of CHIKV infection, a large percentage of the
studied population had persistent anti-CHIKV-speciﬁc anti-
bodies, even if the amount of immunoresponse decreased over
time, as expected. To our knowledge, this is the ﬁrst study to
evaluate the CHIKV-speciﬁc immunoresponse among a popu-
lation living in a temperate area, choosing as starting point for
study inclusion either a laboratory conﬁrmation of viremia or
the detection of a speciﬁc IgM response. In addition, this eval-
uation was performed mainly among a white population, thuss obtained from 133 patients after their acute-phase chikungunya virus
f the antibody titres was calculated (thick red line).
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FIG. 2. Variation of the IgG antibody titres in the three follow-up samplings obtained from 133 patients after their acute-phase chikungunya virus
(CHIKV) infection. For each follow-up group of specimens, the mean value of the antibody titres was calculated (thick red line).
NMNI Pierro et al. Persistence of anti–chikungunya virus 25demonstrating that the immunoresponse against this virus is
not substantially different in diverse geographic zones. Further
studies are warranted to evaluate the variation of the CHIKV-
speciﬁc antibody response over a longer period in order to
assess the persistence of the immune-mediated protection.Conﬂict of interestNone declared.AcknowledgementThis study was supported by “Fondi Lab P3” from Regione
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